Companies › Woolsey Pharmaceuticals
1 active drug program in 5 registered trials: 5 Phase 2; Neurology, Genitourinary, Oncology; next expected readout Jan 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fasudil (WP-0512) Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 2 | Amyotrophic Lateral Sclerosis; Prostate Cancer; Prostate CA; Cognitive Decline, Mild … | Jan 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07250542 | Fasudil (WP-0512) | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT06861192 | Fasudil (WP-0512) | Phase 2 | Prostate CA | Genitourinary | Mar 2027 |
| NCT06362707 | Fasudil (WP-0512) | Phase 2 | Cognitive Decline, Mild | Oncology | Jan 2028 |
| NCT06890858 | Fasudil (WP-0512) | Phase 2 | Ovarian Cancer | Oncology | Jan 2028 |
| NCT05218668 | Fasudil (WP-0512) | Phase 2 | Amyotrophic Lateral Sclerosis | Neurology | Jan 2029 |
Sanofi Aurion Biotech Chia Tai Tianqing Pharmaceutical Group
Leadiant Biosciences Kissei Pharmaceutical Shanghai Jiaolian Drug Research and Development Exciva Guangzhou Novaken Pharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.